Acadia Pharmaceuticals ACAD Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's total current liabilities?
- Acadia Pharmaceuticals (ACAD) reported total current liabilities of $305.52M in Q1 2026.
- How has Acadia Pharmaceuticals's total current liabilities changed year-over-year?
- Acadia Pharmaceuticals's total current liabilities increased by 1.0% year-over-year, from $302.53M to $305.52M.
- What is the long-term trend for Acadia Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total current liabilities has grown at a 21.2% compound annual growth rate (CAGR), from $105.97M to $277.11M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.